CN101376653B - Flavonol compound, and preparation and use thereof - Google Patents
Flavonol compound, and preparation and use thereof Download PDFInfo
- Publication number
- CN101376653B CN101376653B CN2008102334285A CN200810233428A CN101376653B CN 101376653 B CN101376653 B CN 101376653B CN 2008102334285 A CN2008102334285 A CN 2008102334285A CN 200810233428 A CN200810233428 A CN 200810233428A CN 101376653 B CN101376653 B CN 101376653B
- Authority
- CN
- China
- Prior art keywords
- flavonol
- compound
- cpds
- volume ratio
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 235000011957 flavonols Nutrition 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- -1 Flavonol compound Chemical class 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract 4
- 230000001741 anti-phlogistic effect Effects 0.000 claims abstract 3
- 150000007946 flavonol Chemical class 0.000 claims description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 239000000741 silica gel Substances 0.000 claims description 12
- 229910002027 silica gel Inorganic materials 0.000 claims description 12
- 229960001866 silicon dioxide Drugs 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 7
- 239000003480 eluent Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000013375 chromatographic separation Methods 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 12
- 229910052799 carbon Inorganic materials 0.000 description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- TUUXBSASAQJECY-UHFFFAOYSA-N 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C(CC=C(C)C)=C2O1 TUUXBSASAQJECY-UHFFFAOYSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 229940125904 compound 1 Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CTGVBHDTGZUEJZ-UHFFFAOYSA-N Noricaritin Natural products CC(C)(O)CCC1=C(O)C=C(O)C(C(C=2O)=O)=C1OC=2C1=CC=C(O)C=C1 CTGVBHDTGZUEJZ-UHFFFAOYSA-N 0.000 description 6
- 238000006297 dehydration reaction Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 150000002213 flavones Chemical class 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000002516 radical scavenger Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 235000013539 calcium stearate Nutrition 0.000 description 3
- 239000008116 calcium stearate Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 241001362421 Epimedium brevicornu Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940117173 croton oil Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- YHQXBTXEYZIYOV-UHFFFAOYSA-N 3-methylbut-1-ene Chemical group CC(C)C=C YHQXBTXEYZIYOV-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FOGVNFMUZXDMTR-UHFFFAOYSA-N [Mg].Cl Chemical compound [Mg].Cl FOGVNFMUZXDMTR-UHFFFAOYSA-N 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 235000012204 lemonade/lime carbonate Nutrition 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000020245 plant milk Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Abstract
The invention provides a flavonol compound, and also relates to a preparation method thereof, a pharmaceutical composition comprising the same as the active component, and the application of the compound and the pharmaceutical composition on the preparation of antiphlogistic. The compound has remarkable anti-inflammatory effect, and can be expected to be antiphlogistic. The provided flavonol compound has a structure formula as follow.
Description
Technical field
The present invention relates to a kind of flavonol cpds---2 ＂-hydroxyl-3 ＂-alkene-dehydration Icaritin, and the preparation method of this compound and be the pharmaceutical composition of activeconstituents, and the application in treatment inflammation medicine with this compound.
Background technology
In recent years, in the research of anti inflammatory immunity medicine, Chinese medicine reaches characteristics such as aboundresources less because of its good drug efficacy, untoward reaction, more and more receive people's attention.The anti inflammatory immunity medicine is meant inflammatory reaction inhibited, immunoreation is had one type of medicine of inhibition or enhancing and regulating effect.The immunity system of body is the network system of a complicacy; The change of immune certain index often causes the variation of other indexs of body immune system; The anti inflammatory immunity pharmacology has been deep into cell levels and gene level, comprises researchs such as second messenger, nf in cytokine and acceptor thereof, lipoids inflammatory mediator, nitrogen protoxide, active oxygen, the cell.Along with improving constantly of anti-inflammatory pharmacological research method, the especially widespread use of Protocols in Molecular Biology in Chinese medicine anti-inflammatory pharmacological research, researching and developing the new natural drug activeconstituents with anti-inflammatory activity becomes focus gradually.Chinese medicine with antiinflammatory immunity function relates to multiple natural phant kind; Like trypterygine, Stem of Orientoine, the coptis, Chinese herbaceous peony, the Radix Astragali, glossy ganoderma, Herba Epimedii etc., activeconstituents relates to polysaccharide, glycosides, vegeto-alkali, lactone, steroidal, tonka bean camphor, anthraquinone, flavones, tannin, volatilization wet goods.
It is found that flavonoid compound has effects such as anti-inflammatory, antiviral, cholagogic, cardiac stimulant, calmness and analgesia the end of the sixties, found again afterwards that it had anti-oxidant, anti-ageing, immunomodulatory and effect such as antitumor.Epimedium flavonoids on croton oil induced mouse ear edema, acetic acid-induced increase in capillary permeability in mice, carrageenan induced paw edema in mice induced by croton oil and meat Ya tissue significantly inhibited effect on adjuvant arthritis in rats with primary and secondary paw swelling was significantly inhibited paw swelling.
Up to now, do not have the report of the flavonol cpds 2 ＂-hydroxyl-3 ＂-alkene-dehydration Icaritin of novel structure of the present invention in the prior art, also not this compound as effective ingredient in the relevant report of treatment aspect the disease.
Summary of the invention
The object of the present invention is to provide a kind of new flavonol cpds with pharmaceutical use.
Another object of the present invention provides a kind of preparation method of flavonol cpds.
It is the pharmaceutical composition of activeconstituents with the flavonol cpds that further aim of the present invention provides a kind of.
Another purpose of the present invention provides above-mentioned flavonol cpds or the purposes of compsn in preparation anti inflammatory immunity medicine.
Inventors of the present invention isolate a kind of new from dry Herba Epimedii (Epimedium brevicornum Maxim) herb, and it is active to have multiple valuable drug, and these activity are that existing Herba Epimedii plant milk extract is not available.
Flavonol cpds provided by the invention has following structural formula:
Flavonol cpds provided by the invention is extraction separation from the Herba Epimedii herb, and this method may further comprise the steps:
A, dry Herba Epimedii herb pulverized after, press Herba Epimedii: the mass/volume ratio of aqueous acetone solution=1: 2～4, it is 75% aqueous acetone solution that Herba Epimedii is put into concentration; After soaking 15～30 hours under the room temperature; Get extracting solution, so repeat to extract united extraction liquid 2～3 times;
B, with the underpressure distillation of above-mentioned A step gained extracting solution after do not have acetone flavor, press extracting solution: the volume ratio of sherwood oil=1: 1, under room temperature, extracting solution is carried out 2～3 times extraction with sherwood oil, reclaim sherwood oil after, must extraction liquid;
C, press extraction liquid: the volume ratio of ETHYLE ACETATE=1: 1, under room temperature, the extraction liquid of above-mentioned B step is carried out 2～3 times extraction with ETHYLE ACETATE, after the recovery ETHYLE ACETATE medicinal extract;
D, silicagel column on the ETHYLE ACETATE medicinal extract of above-mentioned C step is carried out chromatographic separation, use chloroform: methyl alcohol=40～0: the mixture of 1 volume ratio carries out wash-out as eluent, remove impurity after, the roughing out thing;
E, the roughing out thing of above-mentioned D step is carried out the silica gel column chromatography identical with step D and wash-out 2～5 times, remove impurity after, smart isolate;
F, the smart isolate of E step gained analyzed with efficient liquid phase chromatographic analysis appearance of the prior art after, with getting flavonol cpds after the ZORBAX SB-C18 post of the prior art half preparation separation.
Said flavonol cpds is a yellow powder, and its molecular formula is C
21H
20O
7, degree of unsaturation is 12, structure is: and 3,5,7-trihydroxy--8-(2 ＂-hydroxyl-3 ＂-methyl-3 ＂-crotonyl)-4 '-methoxy flavone is 2 ＂-hydroxyl-3 ＂-alkene-dehydration Icaritin, and its structural formula is following:
The flavonol cpds of structural formula provided by the invention (1) is used the test of MTT detection method and is shown after it is to RAW264.7 cytosis 24h do not have the significant cytotoxicity effect, explains that the cytotoxicity of flavonol cpds is lower.
The flavonol cpds of structural formula provided by the invention (1); Find that through experimental study it is the TNF-α of the adjusting LPS inductive RAW264.7 emiocytosis of concentration dependent; And can significantly improve the IL-10 level; IL-10 can suppress the synthetic of TNF-α, explains that flavonol cpds of the present invention has tangible antiinflammatory immunity function.
Pharmaceutical composition provided by the invention contain the said structure formula (1) of treating significant quantity compound activeconstituents and contain one or more pharmaceutically acceptable carrier or auxiliary materials.
Said pharmaceutically acceptable carrier or auxiliary material are meant pharmaceutical carrier or the auxiliary material that pharmaceutical field is conventional, as: thinners such as water or alcohol, vehicle, perhaps weighting agent such as starch, sucrose; Perhaps tackiness agents such as derivatived cellulose, alginate, gelatin or Vinylpyrrolidone polymer; Perhaps wetting agent such as glycerine, perhaps disintegrating agents such as agar, lime carbonate or sodium hydrogencarbonate, perhaps absorption enhancer such as quaternary ammonium compound; Perhaps tensio-active agent such as cetyl alcohol; Perhaps absorption carrier such as bentonite or kaolin, perhaps talcum powder, calcium stearate and lubricants such as Magnesium Stearate, polyoxyethylene glycol can add other assistant agents such as flavouring agent, sweeting agent in addition in compsn.
The compounds of this invention can compsn form administered through oral, snuffing go into, the mode of rectum or administered parenterally need to be applied to the patient of this treatment.Be used for when oral, can be made into conventional solid preparation such as tablet, pulvis, granula, capsule etc., perhaps process suspension agent or other syrup, the elixir of water or the oil of liquid; When being used for administered parenterally, can be made into injection solution, water or oil-suspending agent.Preferred form is tablet, capsule, suppository, nasal spray or injection.
The various formulations of pharmaceutical composition of the present invention can be according to the conventional working method preparation of pharmaceutical field.After for example making activeconstituents and one or more carriers or auxiliary material mixing, process required formulation by ordinary method.
It is 0.1～99.5% activeconstituents that pharmaceutical composition of the present invention preferably contains mass ratio, and the best mass ratio that preferably contains is 0.5～95% activeconstituents.
The amount of application of The compounds of this invention can change concrete definite according to route of administration, patient age, body weight, the disease type of being treated and severity etc., and its per daily dose can be 0.01～10mg/kg body weight, preferred 0.1～5mg/kg body weight.Can use by one or many.
Description of drawings
Fig. 1 is the HMBC figure of 2 ＂-hydroxyl-3 ＂-alkene-dehydration Icaritin (1);
Fig. 2 is the toxic action of 1 pair of RAW264.7 scavenger cell of compound, and data are represented with the Mean+SEM mode;
Fig. 3 is 1 pair of external LPS inductive RAW264.7 scavenger cell of compound-monocyte TNF-α synthetic influence;
Fig. 4 is the influence of 1 pair of LPS inductive of compound RAW264.7 cell IL-10 synthetic;
Fig. 5 is the process flow sheet of the embodiment of the invention 1.
Embodiment
Through embodiment the present invention is done further describing below, make more complete understanding the present invention of those skilled in the art, but do not limit the present invention in any way.
Embodiment 1
Flavonol cpds i.e. 2 ＂-hydroxyl-3 ＂-alkene-dehydration Icaritin, or 3,5, the preparation of 7-trihydroxy--8-(2 ＂-hydroxyl-3 ＂-methyl-3 ＂-crotonyl)-4 '-methoxy flavone:
After getting dry Herba Epimedii (Epimedium brevicornum Maxim) herb 12kg pulverizing; Press Herba Epimedii: the mass/volume ratio of aqueous acetone solution=1: 3; Using concentration is lixiviate 3 times under the 75% acetone hydroecium temperature, and each acetone water consumption is 35L, soak time 24 hours; After merging No. 3 extracting solutions, underpressure distillation is to there being the acetone flavor; Press extracting solution: the volume ratio of sherwood oil=1: 1, earlier with sherwood oil under room temperature to extracting solution extraction three times, each sherwood oil consumption 10L, reclaim sherwood oil after, get extraction liquid; Press extraction liquid: the volume ratio of ETHYLE ACETATE=1: 1, again with ETHYLE ACETATE under room temperature to extraction liquid extraction three times, each ETHYLE ACETATE consumption 8L, ETHYLE ACETATE medicinal extract 178g; After using granularity to be 100-200 purpose 400g silica gel mixed samples the ETHYLE ACETATE medicinal extract, last silicagel column carries out the chromatography roughing out, and silicagel column is equipped with 2kg (granularity is 200-300 orders) silica gel in being, volume is the glass steel silicagel column of 120 * 1500mm; Use chloroform afterwards: methyl alcohol is respectively: 40: 1, and 20: 1,10: 1; 8: 1,5: 1,4: 1; Seven eluents of 0: 1 (volume ratio), the chromatographic separation thing carried out wash-out after, separate obtaining 7 roughing out things;
With chloroform: the isolate 20g of the eluent wash-out of methyl alcohol=8: 1 volume ratio with silica gel mixed sample after; Last silicagel column (300g silica gel) chromatography; Through chloroform: the eluent of methyl alcohol=100: 1 volume ratio carries out wash-out and obtains the 204.4mg isolate, and this isolate is gone up silica gel column chromatography (0.2g silica gel mixed sample, last 6g silicagel column) once more; And use chloroform: behind the eluent wash-out of methyl alcohol=120: 1 volume ratio, the smart isolate of 26.6mg; Should the essence isolate analyze that (moving phase is 70% methanol through Agilent1200HPLC of the prior art (performance liquid chromatography); 40 ℃ of column temperatures; Residence time t=8.2min) after, with ZORBAX SB-C18 post of the prior art half preparation separate flavonol cpds 20.3mg.
Flavonol cpds is a yellow powder, and hydrochloric acid-magnesium powder and Molish reaction all are positive.FAB
+The MS spectrum provides quasi-molecular ion peak m/z:385 ([M+H]
+), in conjunction with HR-ESI-MS (m/z:385.1294 ([M+H]
+385.1287) and the information that provides of NMR spectrum, calculated value is:, confirm that its molecular formula is C
21H
20O
7, degree of unsaturation is 12.FAB
+The MS spectrum gives the fragmention of 2 characteristics: m/z368 [M+H-OH]
+There is hydroxyl, 313 [M-C in the prompting molecule
4H
7O]
+There is different prenyl in the prompting molecule.
1H-NMR (table-1) (400MHz, DMSO-d
6) δ: 12.31 (1H, s), 10.57 (1H, s); 8.79 (1H s) is respectively 5,7,3 hydroxyl proton signals of flavones, 8.28 (2H, d; J=9.0Hz), 7.09 (2H, d; J=9.0Hz) there is phenyl ring AA ' BB ' spin system in prompting, and 6.34 (1H s) prompts for a phenyl ring five substituted proton signals.3.88 (3H s) prompts for the proton signal of a methoxyl group, and 1.82 (3H s) prompts for a methyl signals, and this methyl possibly be connected with two keys.
13C-NMR (table-1) (100MHz, DMSO-d
6) δ: 99～178ppm has 15 carbon signals, wherein 130.2,114.6 strength of signal be other-2 times of CH strength of signal, possibly be that 2 carbon signals are overlapping, this can by
1Exist AA ' BB ' spin system to be able to proof among the H-NMR, so should there be 17 carbon signals in this zone, removes 15 carbon signals of flavones parent nucleus, also have 2 carbon signals, wherein 110.3 are-CH
2Carbon signal explains there is a terminal double link that 55.7 is the carbon signal of methoxyl group, and 18.1 is the carbon signal of methyl, and 30.3 is the mesomethylene carbon signal in addition, and 75.4 is oxygen containing methine carbon signal.In the HMBC spectrum (description of drawings Fig. 1); Chemical shift has relevant at 5 hydroxyl proton signals of δ 12.31ppm with the carbon signal of δ: 160.1 (C-5), 99.1 (C-6), 104.0 (C-10); The carbon signal of the hydrogen signal and δ of δ 6.34 (H-6): 160.1 (C-5), 163.6 (C-7), 104.8 (C-8), 104.0 (C-10) has relevant; δ 8.28 (H-2 '; H-6 ') carbon signal of hydrogen signal and δ: 146.6 (C-2), 114.6 (C-3 ', 5 '), 161.7 (C-4 ') has relevant, δ 7.09 (H-3 '; 5 ') hydrogen signal and δ: the carbon signal of 146.6 (C-2), 124.8 (C-1 '), 161.7 (C-4 ') has relevant, has confirmed the signal ownership of flavones parent nucleus thus.The carbon signal of the hydrogen signal and δ of δ 3.02 (H-1 ＂): 163.6 (C-7), 104.8 (C-8), 155.3 (C-9), 75.4 (C-2 ＂), 149.1 (C-3 ＂) has relevant; The carbon signal of the hydrogen signal and δ of δ 4.42 (H-2 ＂): 104.8 (C-8), 30.3 (C-1 ＂), 149.1 (C-3 ＂), 110.3 (C-4 ＂), 18.1 (C-5 ＂) has relevant; The carbon signal of δ: the hydrogen signal and δ of 4.43 (Ha-4 ＂), 4.72 (Hb-4 ＂): 75.4 (C-2 ＂), 149.1 (C-3 ＂), 18.1 (C-5 ＂) has relevant; The carbon signal of the hydrogen signal and δ of δ 1.82 (H-5 ＂): 75.4 (C-2 ＂), 149.1 (C-3 ＂), 110.3 (C-4 ＂) has relevant; Can confirm that thus this different isopentene group is connected on 8 of flavones parent nucleus, for: 2 ＂-hydroxyl-3 ＂-methyl-3 ＂-crotonyl.It is relevant that the proton signal of δ 3.88 methoxyl groups and the carbon signal of δ 161.7 (C-4 ') have, and the prompting methoxyl group is connected 4 ' position.
In sum, the structure of flavonol cpds is confirmed as: 3,5, and 7-trihydroxy--8-(2 ＂-hydroxyl-3 ＂-methyl-3 ＂-crotonyl)-4 '-methoxy flavone is 2 ＂-hydroxyl-3 ＂-alkene-dehydration Icaritin, and its structural formula is following:
Embodiment 2
Tablet:
The flavonol cpds 10mg of activeconstituents---structural formula (1)
Lactose 156mg
W-Gum 55mg
Calcium stearate 4mg
The preparation method: activeconstituents, lactose, W-Gum are mixed, and water is evenly moistening, through dry, sieve after, add calcium stearate, after mixing, compacting in flakes, every weighs 225mg, active component content is 10mg.
Embodiment 3
Sprays:
The flavonol cpds 8mg of activeconstituents structural formula (1)
Sodium-chlor 9mg
EDTA 0.5mg
Sodium phosphate buffer (Ph6.5) 10mg
Zero(ppm) water adds to 2ml
Preparing method: after each solids component added in the zero(ppm) water dissolving fully successively, through filtering, after the sterilization, bottling.
Embodiment 4
The anti-inflammatory action of the flavonol cpds of structural formula (1) comprises following testing sequence:
1, material and method
1.1 the cell cultures cell is inoculated in 24 well culture plates after going down to posterity in containing the clear high sugared DMEM substratum of 10% tire ox.Being divided into is three groups, the positive controls (LPS1mg/L handles 18h) that blank control group (no medicine handle with LPS), LPS handle, compound 1 (be respectively 0.5,2.5 and 12.5mg/L)+LPS treatment group, LPS and compound 1 are handled 18h simultaneously, every group respectively three parallel.
1.2 the toxicological evaluation of compound 1 is used the MTT detection method and is estimated.Take the logarithm vegetative period RAW cell inoculation in 96 well culture plates, 1 * 10
5Individual cells/well, 37 ℃, 5%CO
2After cultivating 20h under the condition, add 20 μ LMTT (5mg/mL) again and continue to cultivate 4h, add DMSO150 μ L dissolving then, measure each hole light absorption value (OD value) in the 595nm place, calculate the relevant motility rate of cell with enzyme-linked immunosorbent assay instrument.
1.3 the mensuration of cytokine is got cultured cells supernatant 100 μ L, according to the procedure operation of cytokine ELISA detection kit.
2, result
2.1 behind RAW264.7 monocyte-scavenger cell 20h that the toxicological evaluation 0.5,2.5 of compound 1 and the compound of 12.5mg/L concentration 1 are handled; Handling positive controls with the blank group with LPS compares; The cell motility rate does not have significant difference, explains that 1 pair of RAW264.7 cell of compound does not have cytotoxic effect (description of drawings Fig. 2).
2.2 after 1 pair of external LPS inductive RAW264.7 scavenger cell-monocyte TNF-α synthetic of compound influenced blank control group RAW264.7 cell cultures 18h, excretory TNF-alpha levels was respectively 1433.5 ± 417pg/mL.The secretion of TNF-α significantly increases behind LPS (1mg/L) the processing 18h, reaches 4884 ± 600pg/mL.After adding compound 1 (0.5-12.5mg/L) and LPS co-processing, there is concentration dependent (description of drawings Fig. 3) in RAW264.7 excretory TNF-α.Compare with the positive controls that LPS handles; 0.5 can suppress TNF-α significantly with the compound 1 of 12.5mg/L concentration; Inhibiting rate is respectively 17.1% (p < 0.01); 55.6% (p < 0.01), the compound 1 of 2.5mg/L concentration can suppress TNF-α, but difference not significantly (p>0.05) inhibiting rate be 20.1%.
2.3 the IL-10 that 1 pair of external LPS inductive RAW264.7 cell IL-10 synthetic of compound influences the RAW264.7 emiocytosis of blank group is respectively 19.435 ± 2.32pg/mL, significantly is lower than positive controls 100.64 ± 6.15pg/mL (description of drawings Fig. 4) that LPS handles.For the RAW cell; The IL-10 0.5-12.5mg/L the compound 1 of concentration can raise; The IL-10 level 0.5mg/L the compound 1 of concentration can raise; The compound 1 of the promotion rate is 8% (p>0.05) .2.5 and the 12.5mg/L concentration IL-10 level that can significantly raise is respectively 115.11 ± 14.16pg/mL and 127.6 ± 8.39pg/mL, and the promotion rate is 15% and 27% (p < 0.01).
Table-1 compound 1
1H-NMR with
13C-NMR data (δ: ppm; J:Hz)
Annotate: compound 1
1H-NMR with
13C-NMR measures in 400MHz and 100MHz respectively; Solvent is: DMSO
Claims (4)
1. flavonol cpds has following structural formula:
2. the preparation method of flavonol cpds according to claim 1 is characterized in that comprising the following steps:
A, dry Herba Epimedii herb pulverized after, press Herba Epimedii: the mass/volume ratio of aqueous acetone solution=1: 2～4, i.e. kg/L; It is 75% aqueous acetone solution that Herba Epimedii is put into concentration, soak 15～30 hours under the room temperature after, extracting solution; So repeat to extract united extraction liquid 2～3 times;
B, with the underpressure distillation of above-mentioned A step gained extracting solution after do not have acetone flavor, press extracting solution: the volume ratio of sherwood oil=1: 1, under room temperature, extracting solution is carried out 2～3 times extraction with sherwood oil, reclaim sherwood oil after, must extraction liquid;
C, press extraction liquid: the volume ratio of ETHYLE ACETATE=1: 1, under room temperature, the extraction liquid of above-mentioned B step is carried out 2～3 times extraction with ETHYLE ACETATE, after the recovery ETHYLE ACETATE medicinal extract;
D, silicagel column on the ETHYLE ACETATE medicinal extract of above-mentioned C step is carried out chromatographic separation, use chloroform: methyl alcohol=40～0: the mixture of 1 volume ratio carries out wash-out as eluent, remove impurity after, the roughing out thing;
E, the roughing out thing of above-mentioned D step is carried out the silica gel column chromatography identical with step D and wash-out 2～5 times, remove impurity after, smart isolate;
F, the smart isolate of E step gained analyzed with the efficient liquid phase chromatographic analysis appearance after, with getting flavonol cpds after the half preparation separation of ZORBAX SB-C18 post.
3. be used for antiphlogistic pharmaceutical composition, wherein contain compound and the pharmaceutically acceptable carrier or the auxiliary material of the claim 1 of treating significant quantity.
4. the application of claim 1 compound in the preparation anti-inflammatory drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102334285A CN101376653B (en) | 2008-10-10 | 2008-10-10 | Flavonol compound, and preparation and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102334285A CN101376653B (en) | 2008-10-10 | 2008-10-10 | Flavonol compound, and preparation and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101376653A CN101376653A (en) | 2009-03-04 |
| CN101376653B true CN101376653B (en) | 2012-05-16 |
Family
ID=40420397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008102334285A Expired - Fee Related CN101376653B (en) | 2008-10-10 | 2008-10-10 | Flavonol compound, and preparation and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101376653B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI698245B (en) * | 2017-08-18 | 2020-07-11 | 彥臣生技藥品股份有限公司 | Composition for enhancing immunity of insects and method thereof |
| CN111995628B (en) * | 2020-07-17 | 2023-02-03 | 山东省中医药研究院 | Novel compound extracted from coptis chinensis medicinal material and extraction separation method and application thereof |
| CN113072526B (en) * | 2021-03-30 | 2022-09-13 | 滨州医学院 | Anthraquinone/coumarin dimer compound and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634910A (en) * | 2004-11-11 | 2005-07-06 | 中国药科大学 | Process for preparing epimedium total flavone for injection |
| CN101205223A (en) * | 2006-12-18 | 2008-06-25 | 李毅林 | Total synthesis method of natural product barrenwort glycosides compounds |
-
2008
- 2008-10-10 CN CN2008102334285A patent/CN101376653B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634910A (en) * | 2004-11-11 | 2005-07-06 | 中国药科大学 | Process for preparing epimedium total flavone for injection |
| CN101205223A (en) * | 2006-12-18 | 2008-06-25 | 李毅林 | Total synthesis method of natural product barrenwort glycosides compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101376653A (en) | 2009-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105884621B (en) | A kind of sesquiterpenoids and its preparation method and application | |
| CN110305092A (en) | Guainane sequiterpene and its preparation and application | |
| CN101376653B (en) | Flavonol compound, and preparation and use thereof | |
| CN101648934B (en) | Isopentenyl flavone and application thereof | |
| CN106243120B (en) | The preparation of Sophora alopecuroide flavones Stilbene class extract and its application in cosmetics | |
| CN102977082B (en) | Isocoumarin compound as well as preparation method and application thereof | |
| CN104926772B (en) | Novel flavonoid compound as well as preparation method and uses thereof | |
| CN110452113A (en) | A kind of (4 → 2) reset Crow alkane type diterpene-kind compound and its preparation method and application | |
| CN101891727A (en) | Method for separating and extracting apigenin, acacetin-7-O-beta-D-glucoside and apigenin-7-O-beta-D-glucoside from dendranthema indicum | |
| CN1837226B (en) | Separation of medical derivatives from phoenix-tail fern and use thereof | |
| CN115724812B (en) | Extraction and separation method of furan ester alkaloid in purslane and application of extraction and separation method | |
| CN107522706A (en) | Parallel double tetrahydrofuran lignans and its preparation method and application | |
| CN104262316B (en) | A kind of flavonoid compound and its preparation method and application | |
| CN102887928B (en) | Flavonoids from nervilia fordii and preparation method and use thereof | |
| CN114276966B (en) | Astragalus endophytic bacterium for producing isoflavone component and application thereof | |
| Oshima et al. | Schizonodiol, schizonol, and schizonepetosides D and E, monoterpenoids of Schizonepeta tenuifolia spikes | |
| CN104761525A (en) | Flavonoid compound, and preparation method and application thereof | |
| CN111253352B (en) | Compound extracted and separated from traditional Chinese medicine cymbidium maculatum, and preparation method and application thereof | |
| Ahmed | New flavone from the aerial parts of Bougainvillea glabra | |
| CN106565444A (en) | Extraction method and application of phenanthrene compounds from overground part of Chinese yam | |
| CN103450209B (en) | Isoflavonoid and preparation method thereof and application in large fruit banyan | |
| CN102633784A (en) | Two new flavone C-glycoside compounds as well as preparation method and application thereof | |
| CN112898357A (en) | Diterpene glycoside novel compound in trollius chinensis bunge and separation and purification method and application thereof | |
| CN104151375B (en) | A kind of the Kunlun snow chrysanthemum phenolic glycoside compound and its production and use | |
| CN102600126B (en) | Application of prenylated flavonoid compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120516 Termination date: 20141010 |
|
| EXPY | Termination of patent right or utility model |